Almudena Cascajero
YOU?
Author Swipe
View article: Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants Open
View article: Characterisation of Legionella Clinical Isolates in Spain from 2012 to 2022
Characterisation of Legionella Clinical Isolates in Spain from 2012 to 2022 Open
Although cases of Legionnaires’ disease are notifiable, data on the phenotypic and genotypic characterisation of clinical isolates are limited. This retrospective study aims to report the results of the characterisation of Legionella clini…
View article: Fulminant septic shock due to community-acquired pneumonia caused by Legionella pneumophila SG1 Olda OLDA ST1. Case report
Fulminant septic shock due to community-acquired pneumonia caused by Legionella pneumophila SG1 Olda OLDA ST1. Case report Open
Legionellers' desease accounts for 1-8 % of cases of severe community-acquired pneumonia (CAP). Legionella spp. Is the causative organism that can result in respiratory failure, multi-organ dysfunction, sepsis, and death. Therefore, rapid …
View article: Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern
Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern Open
The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants of concern elicited by vaccination was evaluated in COVID‐19 recovered individuals (Rec) separated 1–3 months (Rec2m) or 4–12 months …
View article: Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV
Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV Open
The presence of neutralizing antibodies (NAbs) is a major correlate of protection for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Thus, different in vitro pseudoviruses‐based assays have been described to detect…
View article: Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19 Open
View article: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial Open
View article: Cellular and Humoral Functional Responses After BNT162b2 SARS-CoV-2 mRNA Vaccination Differ Between Naïve and COVID-19-Recovered Individuals
Cellular and Humoral Functional Responses After BNT162b2 SARS-CoV-2 mRNA Vaccination Differ Between Naïve and COVID-19-Recovered Individuals Open
View article: Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc
Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc Open
In this study, we have characterized quasispecies dynamics and the evolution of viral tropism in naive HIV-1-infected patients treated with a short course of maraviroc monotherapy (ClinicalTrials.gov registration no. NCT01060618) independe…
View article: A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity
A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity Open